Literature DB >> 25567663

Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer.

Birte Kulemann1, Jens Hoeppner, Uwe Wittel, Torben Glatz, Tobias Keck, Ulrich F Wellner, Peter Bronsert, Olivia Sick, Ulrich T Hopt, Frank Makowiec, Hartwig Riediger.   

Abstract

INTRODUCTION: The value of extended resection (portal vein, multivisceral) in patients with pancreatic adenocarcinoma (PDAC) is not well defined. We analyzed the outcome after standard resection (standard pancreaticoduodenectomy (SPR)), additional portal vein (PV) and multivisceral (MV) resection in PDAC patients.
METHODS: Clinicopathologic, perioperative, and survival data of patients undergoing pancreatic head resection (PHR) for PDAC 1994-2014 were reviewed from a prospective database.
RESULTS: Three hundred fifty nine patients had PHR for PDAC: 208 (58 %) underwent SPR, 131 (36 %) additional PV, and 20 (6 %) MV. The postoperative complication rate in MV (65 %) was slightly higher than in PV (56 %) or SPR (50 %; p = 0.32). MV patients had higher in-hospital mortality (10 %) than SPR (3.8 %) and PV (1.5 %) patients (p = 0.12). Nodal status was comparable, whereas more patients in PV and MV had final R0 resection (p = 0.02). Five-year survival was 7 % after MV versus 17 % in patients without MV (p = 0.07). Multivariate survival analysis identified resection margin, nodal disease, blood transfusions, and MV are set as independent risk factors for overall survival.
CONCLUSION: Multivisceral pancreatic head resections for PDAC are associated with increased perioperative morbidity and mortality, without improving oncologic outcome. Portal vein resection can be performed safely to reach R0 resection and its survival benefits.

Entities:  

Mesh:

Year:  2015        PMID: 25567663     DOI: 10.1007/s11605-014-2725-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  28 in total

1.  RADICAL PANCREATODUODENECTOMY AND PORTAL VEIN RESECTION. REPORT OF TWO SUCCESSFUL CASES WITH TRANSPLANTATION OF PORTAL VEIN.

Authors:  S ASADA; H ITAYA; K NAKAMURA; T ISOHASHI; S MASUOKA
Journal:  Arch Surg       Date:  1963-10

Review 2.  Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review.

Authors:  Terence C Chua; Akshat Saxena
Journal:  J Gastrointest Surg       Date:  2010-04-09       Impact factor: 3.452

3.  Most pancreatic cancer resections are R1 resections.

Authors:  Irene Esposito; Jörg Kleeff; Frank Bergmann; Caroline Reiser; Esther Herpel; Helmut Friess; Peter Schirmacher; Markus W Büchler
Journal:  Ann Surg Oncol       Date:  2008-03-20       Impact factor: 5.344

4.  Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.

Authors:  J L Cameron; D W Crist; J V Sitzmann; R H Hruban; J K Boitnott; A J Seidler; J Coleman
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

5.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

6.  Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study.

Authors:  Reena Ravikumar; Caroline Sabin; Mohammad Abu Hilal; Simon Bramhall; Steven White; Stephen Wigmore; Charles J Imber; Giuseppe Fusai
Journal:  J Am Coll Surg       Date:  2013-11-27       Impact factor: 6.113

Review 7.  Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.

Authors:  V Heinemann; M Haas; S Boeck
Journal:  Ann Oncol       Date:  2013-07-12       Impact factor: 32.976

8.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

9.  Perioperative mortality for pancreatectomy: a national perspective.

Authors:  James T McPhee; Joshua S Hill; Giles F Whalen; Maksim Zayaruzny; Demetrius E Litwin; Mary E Sullivan; Frederick A Anderson; Jennifer F Tseng
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

10.  Additional organ resection combined with pancreaticoduodenectomy does not increase postoperative morbidity and mortality.

Authors:  Mehrdad Nikfarjam; Mandeep Sehmbey; Eric T Kimchi; Niraj J Gusani; Serene Shereef; Diego M Avella; Kevin F Staveley-O'Carroll
Journal:  J Gastrointest Surg       Date:  2009-02-07       Impact factor: 3.452

View more
  22 in total

1.  Surgical, survival, and oncological outcomes after vascular resection in robotic and open pancreaticoduodenectomy.

Authors:  Bor-Uei Shyr; Shih-Chin Chen; Yi-Ming Shyr; Shin-E Wang
Journal:  Surg Endosc       Date:  2019-04-08       Impact factor: 4.584

2.  Perioperative Complications and Outcomes after Intestinal Autotransplantation for Neoplasms Involving the Superior Mesenteric Artery.

Authors:  Guosheng Wu; Qingchuan Zhao; Xiaohua Li; Mian Wang; Hao Sun; Jingson Zhang; Zengshan Li; Jianyong Zheng; Mengbin Li; Daiming Fan
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

3.  Results of portosystemic shunts during extended pancreatic resections.

Authors:  Florian Oehme; Marius Distler; Benjamin Müssle; Christoph Kahlert; Jürgen Weitz; Thilo Welsch
Journal:  Langenbecks Arch Surg       Date:  2019-08-24       Impact factor: 3.445

Review 4.  Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival.

Authors:  Marianne Sinn; Marcus Bahra; Timm Denecke; Sue Travis; Uwe Pelzer; Hanno Riess
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

5.  Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors.

Authors:  Abhishek Mitra; Esha Pai; Rohit Dusane; Priya Ranganathan; Ashwin DeSouza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2018-01-23       Impact factor: 3.445

6.  A pooled analysis of en bloc right hemicolectomy with pancreaticoduodenectomy for locally advanced right-sided colon cancer.

Authors:  Debang Li; Xiaoying Si; Tao Wan; Yanming Zhou
Journal:  Int J Colorectal Dis       Date:  2018-03-02       Impact factor: 2.571

7.  Robotic-assisted versus open pancreaticoduodenectomy for patients with benign and malignant periampullary disease: a systematic review and meta-analysis of short-term outcomes.

Authors:  Mauro Podda; Chiara Gerardi; Salomone Di Saverio; Marco Vito Marino; R Justin Davies; Gianluca Pellino; Adolfo Pisanu
Journal:  Surg Endosc       Date:  2020-02-18       Impact factor: 4.584

Review 8.  Pancreatoduodenectomy associated with colonic resections: indications, pitfalls, and outcomes.

Authors:  Tommaso Giuliani; Anthony Di Gioia; Stefano Andrianello; Giovanni Marchegiani; Claudio Bassi
Journal:  Updates Surg       Date:  2021-02-13

9.  Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: an in vivo and in vitro study.

Authors:  Haisu Dai; Haowei Chen; Wei Liu; Yu You; Jiaxin Tan; Aigang Yang; Xiangdong Lai; Ping Bie
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-21       Impact factor: 4.553

10.  [Resection for advanced pancreatic cancer following multimodal therapy].

Authors:  J Kleeff; C Stöß; V Yip; W T Knoefel
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.